Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Tyrosinase (EC 1.14.18.1) (LB24-AB) (Monophenol monooxygenase) (SK29-AB) (Tumor rejection antigen AB)

 TYRO_HUMAN              Reviewed;         529 AA.
P14679; Q15675; Q15676; Q15680; Q8TAK4; Q9BYY0; Q9BZX1;
01-APR-1990, integrated into UniProtKB/Swiss-Prot.
01-JUL-1993, sequence version 3.
27-SEP-2017, entry version 198.
RecName: Full=Tyrosinase;
EC=1.14.18.1;
AltName: Full=LB24-AB;
AltName: Full=Monophenol monooxygenase;
AltName: Full=SK29-AB;
AltName: Full=Tumor rejection antigen AB;
Flags: Precursor;
Name=TYR;
Homo sapiens (Human).
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
Catarrhini; Hominidae; Homo.
NCBI_TaxID=9606;
[1]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
PubMed=1903356; DOI=10.1016/0888-7543(91)90409-8;
Giebel L.B., Strunk K.M., Spritz R.A.;
"Organization and nucleotide sequences of the human tyrosinase gene
and a truncated tyrosinase-related segment.";
Genomics 9:435-445(1991).
[2]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
PubMed=2823263; DOI=10.1073/pnas.84.21.7473;
Kwon B.S., Haq A.K., Pomerantz S.H., Halaban R.;
"Isolation and sequence of a cDNA clone for human tyrosinase that maps
at the mouse c-albino locus.";
Proc. Natl. Acad. Sci. U.S.A. 84:7473-7477(1987).
[3]
ERRATUM, AND SEQUENCE REVISION TO 384-398.
Kwon B.S., Haq A.K., Pomerantz S.H., Halaban R.;
Proc. Natl. Acad. Sci. U.S.A. 85:6352-6352(1988).
[4]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
TISSUE=Melanoma;
PubMed=2499655; DOI=10.1084/jem.169.6.2029;
Bouchard B., Fuller B.B., Vijayasaradhi S., Houghton A.N.;
"Induction of pigmentation in mouse fibroblasts by expression of human
tyrosinase cDNA.";
J. Exp. Med. 169:2029-2042(1989).
[5]
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
PubMed=1711223; DOI=10.1073/pnas.88.12.5272;
Chintamaneni C.D., Halaban R., Kobayashi Y., Witkop C.J., Kwon B.S.;
"A single base insertion in the putative transmembrane domain of the
tyrosinase gene as a cause for tyrosinase-negative oculocutaneous
albinism.";
Proc. Natl. Acad. Sci. U.S.A. 88:5272-5276(1991).
[6]
NUCLEOTIDE SEQUENCE (ISOFORM 1).
TISSUE=Melanoma, and T-cell;
PubMed=8340755; DOI=10.1084/jem.178.2.489;
Brichard V., van Pel A., Woelfel T., Woelfel C., de Plaen E.,
Lethe B.G., Coulie P., Boon T.;
"The tyrosinase gene codes for an antigen recognized by autologous
cytolytic T lymphocytes on HLA-A2 melanomas.";
J. Exp. Med. 178:489-495(1993).
[7]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1), AND VARIANT TYR-192.
PubMed=11153699; DOI=10.1034/j.1600-0749.2000.130609.x;
Martinez-Arias R., Comas D., Andres A., Abello M.-T.,
Domingo-Roura X., Bertranpetit J.;
"The tyrosinase gene in gorillas and the albinism of 'Snowflake'.";
Pigment Cell Res. 13:467-470(2000).
[8]
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
TISSUE=Skin;
PubMed=15489334; DOI=10.1101/gr.2596504;
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA
project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
[9]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-272.
TISSUE=Liver;
PubMed=2480811; DOI=10.1016/0167-4781(89)90115-2;
Kikuchi H., Miura H., Yamamoto H., Takeuchi T., Dei T., Watanabe M.;
"Characteristic sequences in the upstream region of the human
tyrosinase gene.";
Biochim. Biophys. Acta 1009:283-286(1989).
[10]
NUCLEOTIDE SEQUENCE [MRNA] OF 1-32.
PubMed=2504160; DOI=10.1016/0006-291X(89)90770-5;
Takeda A., Tomita Y., Okinaga S., Tagami H., Shibahara S.;
"Functional analysis of the cDNA encoding human tyrosinase
precursor.";
Biochem. Biophys. Res. Commun. 162:984-990(1989).
[11]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 54-195, AND VARIANT TYR-192.
PubMed=11214319; DOI=10.1038/35054550;
Murphy W.J., Eizirik E., Johnson W.E., Zhang Y.-P., Ryder O.A.,
O'Brien S.J.;
"Molecular phylogenetics and the origins of placental mammals.";
Nature 409:614-618(2001).
[12]
REVIEW ON OCA VARIANTS.
PubMed=8477259; DOI=10.1002/humu.1380020102;
Oetting W.S., King R.A.;
"Molecular basis of type I (tyrosinase-related) oculocutaneous
albinism: mutations and polymorphisms of the human tyrosinase gene.";
Hum. Mutat. 2:1-6(1993).
[13]
REVIEW ON OCA1 VARIANTS.
PubMed=10094567;
DOI=10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3;
Oetting W.S., King R.A.;
"Molecular basis of albinism: mutations and polymorphisms of
pigmentation genes associated with albinism.";
Hum. Mutat. 13:99-115(1999).
[14]
SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
TISSUE=Melanoma;
PubMed=12643545; DOI=10.1021/pr025562r;
Basrur V., Yang F., Kushimoto T., Higashimoto Y., Yasumoto K.,
Valencia J., Muller J., Vieira W.D., Watabe H., Shabanowitz J.,
Hearing V.J., Hunt D.F., Appella E.;
"Proteomic analysis of early melanosomes: identification of novel
melanosomal proteins.";
J. Proteome Res. 2:69-79(2003).
[15]
SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
TISSUE=Melanoma;
PubMed=17081065; DOI=10.1021/pr060363j;
Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
Hunt D.F.;
"Proteomic and bioinformatic characterization of the biogenesis and
function of melanosomes.";
J. Proteome Res. 5:3135-3144(2006).
[16]
VARIANTS OCA1A LYS-373 AND ASN-383, AND VARIANTS TYR-192 AND GLN-402.
PubMed=2342539; DOI=10.1056/NEJM199006143222407;
Spritz R.A., Strunk K.M., Giebel L.B., King R.A.;
"Detection of mutations in the tyrosinase gene in a patient with type
IA oculocutaneous albinism.";
N. Engl. J. Med. 322:1724-1728(1990).
[17]
VARIANT OCA1A LEU-81.
PubMed=1970634; DOI=10.1073/pnas.87.9.3255;
Giebel L.B., Strunk K.M., King R.A., Hanifin J.M., Spritz R.A.;
"A frequent tyrosinase gene mutation in classic, tyrosinase-negative
(type IA) oculocutaneous albinism.";
Proc. Natl. Acad. Sci. U.S.A. 87:3255-3258(1990).
[18]
VARIANTS OCA1B PHE-275 AND LEU-406.
PubMed=1903591;
Giebel L.B., Tripathi R.K., Strunk K.M., Hanifin J.M., Jackson C.E.,
King R.A., Spritz R.A.;
"Tyrosinase gene mutations associated with type IB ('yellow')
oculocutaneous albinism.";
Am. J. Hum. Genet. 48:1159-1167(1991).
[19]
ERRATUM.
Giebel L.B., Tripathi R.K., Strunk K.M., Hanifin J.M., Jackson C.E.,
King R.A., Spritz R.A.;
Am. J. Hum. Genet. 49:696-696(1991).
[20]
VARIANTS OCA1A SER-21; TRP-217; HIS-299; SER-403; SER-446 AND ASN-448.
PubMed=1642278; DOI=10.1002/ajmg.1320430523;
Tripathi R.K., Strunk K.M., Giebel L.B., Weleber R.G., Spritz R.A.;
"Tyrosinase gene mutations in type I (tyrosinase-deficient)
oculocutaneous albinism define two clusters of missense
substitutions.";
Am. J. Med. Genet. 43:865-871(1992).
[21]
VARIANT OCA1A ARG-89.
PubMed=1899321;
Spritz R.A., Strunk K.M., Hsieh C.-L., Sekhon G.S., Francke U.;
"Homozygous tyrosinase gene mutation in an American black with
tyrosinase-negative (type IA) oculocutaneous albinism.";
Am. J. Hum. Genet. 48:318-324(1991).
[22]
VARIANT OCA1B GLN-422.
PubMed=1900309; DOI=10.1172/JCI115075;
Giebel L.B., Tripathi R.K., King R.A., Spritz R.A.;
"A tyrosinase gene missense mutation in temperature-sensitive type I
oculocutaneous albinism. A human homologue to the Siamese cat and the
Himalayan mouse.";
J. Clin. Invest. 87:1119-1122(1991).
[23]
VARIANTS OCA1A GLY-42; TYR-55; THR-206 AND ARG-419.
PubMed=1943686;
King R.A., Mentink M.M., Oetting W.S.;
"Non-random distribution of missense mutations within the human
tyrosinase gene in type I (tyrosinase-related) oculocutaneous
albinism.";
Mol. Biol. Med. 8:19-29(1991).
[24]
VARIANTS OCA1A ILE-176 AND GLN-217.
PubMed=1487241; DOI=10.1007/BF00220074;
Oetting W.S., King R.A.;
"Molecular analysis of type I-A (tyrosinase negative) oculocutaneous
albinism.";
Hum. Genet. 90:258-262(1992).
[25]
VARIANTS OCA1A GLN-328; ARG-419 AND LEU-431.
PubMed=7902671;
Tripathi R.K., Bundey S., Musarella M.A., Droetto S., Strunk K.M.,
Holmes S.A., Spritz R.A.;
"Mutations of the tyrosinase gene in Indo-Pakistani patients with type
I (tyrosinase-deficient) oculocutaneous albinism (OCA).";
Am. J. Hum. Genet. 53:1173-1179(1993).
[26]
VARIANTS OCA1A ASP-47; CYS-217 DEL; HIS-299 AND LYS-373, AND VARIANTS
OCA1B SER-152 AND LYS-294.
PubMed=8128955;
Gershoni-Baruch R., Rosenmann A., Droetto S., Holmes S.A.,
Tripathi R.K., Spritz R.A.;
"Mutations of the tyrosinase gene in patients with oculocutaneous
albinism from various ethnic groups in Israel.";
Am. J. Hum. Genet. 54:586-594(1994).
[27]
VARIANTS OCA1A TYR-367; THR-370 AND LYS-373, AND VARIANT GLN-402.
PubMed=7955413; DOI=10.1016/0009-8981(94)90131-7;
Breimer L.H., Winder A.F., Jay B., Jay M.;
"Initiation codon mutation of the tyrosinase gene as a cause of human
albinism.";
Clin. Chim. Acta 227:17-22(1994).
[28]
VARIANTS OCA1A ARG-361 AND TYR-371.
PubMed=8644824; DOI=10.1016/S0002-9394(14)70647-6;
Summers C.G., Oetting W.S., King R.A.;
"Diagnosis of oculocutaneous albinism with molecular analysis.";
Am. J. Ophthalmol. 121:724-726(1996).
[29]
VARIANT GLN-402.
PubMed=9158138; DOI=10.1093/hmg/6.5.659;
Morell R., Spritz R.A., Ho L., Pierpont J., Guo W., Friedman T.B.,
Asher J.H. Jr.;
"Apparent digenic inheritance of Waardenburg syndrome type 2 (WS2) and
autosomal recessive ocular albinism (AROA).";
Hum. Mol. Genet. 6:659-664(1997).
[30]
VARIANTS OCA1A AND OCA1B.
PubMed=9259202;
DOI=10.1002/(SICI)1098-1004(1997)10:2<171::AID-HUMU11>3.0.CO;2-X;
Spritz R.A., Oh J., Fukai K., Holmes S.A., Ho L., Chitayat D.,
France T.D., Musarella M.A., Orlow S.J., Schnur R.E., Weleber R.G.,
Levin A.V.;
"Novel mutations of the tyrosinase (TYR) gene in type I oculocutaneous
albinism (OCA1).";
Hum. Mutat. 10:171-174(1997).
[31]
VARIANTS OCA1A AND OCA1B.
PubMed=10671066;
DOI=10.1002/(SICI)1098-1004(1998)12:6<433::AID-HUMU14>3.3.CO;2-7;
Oetting W.S., Fryer J.P., King R.A.;
"Mutations of the human tyrosinase gene associated with tyrosinase
related oculocutaneous albinism (OCA1).";
Hum. Mutat. 12:433-434(1998).
[32]
ERRATUM.
Oetting W.S., Fryer J.P., King R.A.;
Hum. Mutat. 13:83-83(1999).
[33]
VARIANTS OCA1A TYR-36; GLN-77; TRP-77; LEU-81; ARG-97; GLN-217;
TRP-217; SER-236; CYS-272; ARG-289; GLY-294; LYS-294; PRO-355;
TYR-371; LYS-373; LEU-406; ARG-419; GLN-422; VAL-439; SER-446 AND
ASN-448, VARIANT OCA1B SER-403, AND VARIANTS TYR-192 AND GLN-402.
PubMed=10987646; DOI=10.1007/s004390051090;
Passmore L.A., Kaesmann-Kellner B., Weber B.H.F.;
"Novel and recurrent mutations in the tyrosinase gene and the P gene
in the German albino population.";
Hum. Genet. 105:200-210(1999).
[34]
ERRATUM.
Passmore L.A., Kaesmann-Kellner B., Weber B.H.F.;
Hum. Genet. 108:208-208(2001).
[35]
VARIANTS OCA1A TYR-55; ARG-77 INS; GLY-289; HIS-299; SER-299 AND
LEU-400.
PubMed=10571953;
DOI=10.1002/(SICI)1098-1004(199912)14:6<542::AID-HUMU14>3.0.CO;2-3;
Tsai C.-H., Tsai F.-J., Wu J.-Y., Lin S.-P., Chang J.-G., Yang C.-F.,
Lee C.-C.;
"Insertion/deletion mutations of type I oculocutaneous albinism in
Chinese patients from Taiwan.";
Hum. Mutat. 14:542-542(1999).
[36]
VARIANTS OCA1A ASP-47; GLN-77; ARG-109; THR-205; TYR-256; PHE-275;
LYS-294; GLY-339; PRO-355; LYS-373; ASN-383 AND SER-446.
PubMed=11295837; DOI=10.1002/humu.38;
Camand O., Marchant D., Boutboul S., Pequignot M., Odent S.,
Dollfus H., Sutherland J., Levin A., Menasche M., Marsac C.,
Dufier J.-L., Heon E., Abitbol M.;
"Mutation analysis of the tyrosinase gene in oculocutaneous
albinism.";
Hum. Mutat. 17:352-352(2001).
[37]
VARIANT OCA1A TRP-239.
PubMed=11858948; DOI=10.1016/S0923-1811(01)00141-4;
Nakamura E., Miyamura Y., Matsunaga J., Kano Y., Dakeishi-Hara M.,
Tanita M., Kono M., Tomita Y.;
"A novel mutation of the tyrosinase gene causing oculocutaneous
albinism type 1 (OCA1).";
J. Dermatol. Sci. 28:102-105(2002).
[38]
VARIANTS OCA1A ARG-44; GLY-44; ASP-47; VAL-47; HIS-68; GLN-77; LEU-79;
LEU-81; SER-155; PHE-177; LEU-179; ASN-180; ASN-199; SER-201; SER-217;
LEU-236; VAL-240; THR-243; TYR-256; ARG-289; GLU-318; PRO-329;
THR-332; GLY-345; PRO-355; LYS-373; LYS-378; ASN-383; PHE-393;
ARG-395; VAL-398; ALA-398; LEU-402; SER-403; ASN-404; LEU-405;
LEU-406; HIS-408; ASP-409; SER-416; HIS-417; ARG-419; GLN-422;
PHE-424; LYS-426; GLY-427; ILE-434; ASP-435; GLY-444 AND ASN-448, AND
VARIANTS TYR-192 AND GLN-402.
PubMed=15146472; DOI=10.1002/humu.9248;
Opitz S., Kaesmann-Kellner B., Kaufmann M., Schwinger E., Zuehlke C.;
"Detection of 53 novel DNA variations within the tyrosinase gene and
accumulation of mutations in 17 patients with albinism.";
Hum. Mutat. 23:630-631(2004).
[39]
VARIANT TYR-192, AND ASSOCIATION WITH SHEP3.
PubMed=17999355; DOI=10.1086/522235;
Stokowski R.P., Pant P.V.K., Dadd T., Fereday A., Hinds D.A.,
Jarman C., Filsell W., Ginger R.S., Green M.R., van der Ouderaa F.J.,
Cox D.R.;
"A genomewide association study of skin pigmentation in a South Asian
population.";
Am. J. Hum. Genet. 81:1119-1132(2007).
[40]
VARIANT TYR-192, AND ASSOCIATION WITH SHEP3.
PubMed=17952075; DOI=10.1038/ng.2007.13;
Sulem P., Gudbjartsson D.F., Stacey S.N., Helgason A., Rafnar T.,
Magnusson K.P., Manolescu A., Karason A., Palsson A., Thorleifsson G.,
Jakobsdottir M., Steinberg S., Palsson S., Jonasson F.,
Sigurgeirsson B., Thorisdottir K., Ragnarsson R.,
Benediktsdottir K.R., Aben K.K., Kiemeney L.A., Olafsson J.H.,
Gulcher J., Kong A., Thorsteinsdottir U., Stefansson K.;
"Genetic determinants of hair, eye and skin pigmentation in
Europeans.";
Nat. Genet. 39:1443-1452(2007).
[41]
VARIANT OCA1A TYR-91.
PubMed=22981120; DOI=10.1016/j.ajhg.2012.08.007;
Chong J.X., Ouwenga R., Anderson R.L., Waggoner D.J., Ober C.;
"A population-based study of autosomal-recessive disease-causing
mutations in a founder population.";
Am. J. Hum. Genet. 91:608-620(2012).
[42]
VARIANTS OCA1A LEU-50; TRP-77; PHE-275; TRP-298; VAL-355; HIS-364;
LYS-373; ALA-384 AND ASP-490.
PubMed=23504663; DOI=10.1002/humu.22315;
Simeonov D.R., Wang X., Wang C., Sergeev Y., Dolinska M., Bower M.,
Fischer R., Winer D., Dubrovsky G., Balog J.Z., Huizing M., Hart R.,
Zein W.M., Gahl W.A., Brooks B.P., Adams D.R.;
"DNA variations in oculocutaneous albinism: an updated mutation list
and current outstanding issues in molecular diagnostics.";
Hum. Mutat. 34:827-835(2013).
[43]
VARIANT OCA1A THR-198.
PubMed=24934919; DOI=10.1111/ced.12382;
Shah S.A., Din S.U., Raheem N., Daud S., Mubeen J., Nadeem A.,
Tayyab M., Baloch D.M., Babar M.E., Ahmad J.;
"Identification of a novel mutation (p.Ile198Thr) in gene TYR in a
Pakistani family with nonsyndromic oculocutaneous albinism.";
Clin. Exp. Dermatol. 39:646-648(2014).
-!- FUNCTION: This is a copper-containing oxidase that functions in
the formation of pigments such as melanins and other polyphenolic
compounds. Catalyzes the initial and rate limiting step in the
cascade of reactions leading to melanin production from tyrosine.
In addition to hydroxylating tyrosine to DOPA (3,4-
dihydroxyphenylalanine), also catalyzes the oxidation of DOPA to
DOPA-quinone, and possibly the oxidation of DHI (5,6-
dihydroxyindole) to indole-5,6 quinone.
{ECO:0000250|UniProtKB:P11344}.
-!- CATALYTIC ACTIVITY: 2 L-dopa + O(2) = 2 dopaquinone + 2 H(2)O.
{ECO:0000250|UniProtKB:P11344}.
-!- CATALYTIC ACTIVITY: L-tyrosine + O(2) = dopaquinone + H(2)O.
{ECO:0000250|UniProtKB:P11344}.
-!- COFACTOR:
Name=Cu(2+); Xref=ChEBI:CHEBI:29036;
Evidence={ECO:0000250|UniProtKB:Q9ZP19};
Note=Binds 2 copper ions per subunit.
{ECO:0000250|UniProtKB:Q9ZP19};
-!- SUBCELLULAR LOCATION: Melanosome membrane
{ECO:0000269|PubMed:12643545, ECO:0000269|PubMed:17081065};
Single-pass type I membrane protein {ECO:0000269|PubMed:12643545,
ECO:0000269|PubMed:17081065}. Melanosome
{ECO:0000250|UniProtKB:P11344}. Note=Proper trafficking to
melanosome is regulated by SGSM2, ANKRD27, RAB9A, RAB32 and RAB38.
{ECO:0000250|UniProtKB:P11344}.
-!- ALTERNATIVE PRODUCTS:
Event=Alternative splicing; Named isoforms=2;
Name=1;
IsoId=P14679-1; Sequence=Displayed;
Name=2;
IsoId=P14679-2; Sequence=VSP_006701, VSP_006702;
Note=No experimental confirmation available.;
-!- INDUCTION: Increased expression after UVB irradiation.
-!- PTM: Glycosylated. {ECO:0000250|UniProtKB:P11344}.
-!- POLYMORPHISM: Genetic variants in TYR define the skin/hair/eye
pigmentation variation locus 3 (SHEP3) [MIM:601800]. Hair, eye and
skin pigmentation are among the most visible examples of human
phenotypic variation, with a broad normal range that is subject to
substantial geographic stratification. In the case of skin,
individuals tend to have lighter pigmentation with increasing
distance from the equator. By contrast, the majority of variation
in human eye and hair color is found among individuals of European
ancestry, with most other human populations fixed for brown eyes
and black hair. {ECO:0000269|PubMed:17952075,
ECO:0000269|PubMed:17999355}.
-!- POLYMORPHISM: Compound heterozygosity for the R402Q polymorphism
and a mutant allele of TYR is a common cause of autosomal
recessive ocular albinism. The R402Q polymorphism is also found in
Waardenburg syndrome type II with ocular albinism (WS2-OA) in
association with a deletion in the MITF gene.
{ECO:0000269|PubMed:2342539, ECO:0000269|PubMed:7955413,
ECO:0000269|PubMed:9158138}.
-!- DISEASE: Albinism, oculocutaneous, 1A (OCA1A) [MIM:203100]: An
autosomal recessive disorder in which the biosynthesis of melanin
pigment is absent in skin, hair, and eyes. It is characterized by
complete lack of tyrosinase activity due to production of an
inactive enzyme. Patients present with a life-long absence of
melanin pigment after birth, and manifest increased sensitivity to
ultraviolet radiation with predisposition to skin cancer. Visual
anomalies include decreased acuity, nystagmus, strabismus and
photophobia. {ECO:0000269|PubMed:10571953,
ECO:0000269|PubMed:10671066, ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:11295837, ECO:0000269|PubMed:11858948,
ECO:0000269|PubMed:1487241, ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:1642278, ECO:0000269|PubMed:1899321,
ECO:0000269|PubMed:1943686, ECO:0000269|PubMed:1970634,
ECO:0000269|PubMed:22981120, ECO:0000269|PubMed:2342539,
ECO:0000269|PubMed:23504663, ECO:0000269|PubMed:24934919,
ECO:0000269|PubMed:7902671, ECO:0000269|PubMed:7955413,
ECO:0000269|PubMed:8128955, ECO:0000269|PubMed:8644824,
ECO:0000269|PubMed:9259202}. Note=The disease is caused by
mutations affecting the gene represented in this entry.
-!- DISEASE: Albinism, oculocutaneous, 1B (OCA1B) [MIM:606952]: An
autosomal recessive disorder in which the biosynthesis of melanin
pigment is reduced in skin, hair, and eyes. It is characterized by
partial lack of tyrosinase activity. Patients have white hair at
birth that rapidly turns yellow or blond. They manifest the
development of minimal-to-moderate amounts of cutaneous and ocular
pigment. Some patients may have with white hair in the warmer
areas (scalp and axilla) and progressively darker hair in the
cooler areas (extremities). This variant phenotype is due to a
loss of tyrosinase activity above 35-37 degrees C.
{ECO:0000269|PubMed:10987646, ECO:0000269|PubMed:1900309,
ECO:0000269|PubMed:1903591, ECO:0000269|PubMed:8128955}. Note=The
disease is caused by mutations affecting the gene represented in
this entry.
-!- SIMILARITY: Belongs to the tyrosinase family. {ECO:0000305}.
-!- SEQUENCE CAUTION:
Sequence=AAA61241.1; Type=Erroneous initiation; Evidence={ECO:0000305};
Sequence=CAA68756.1; Type=Erroneous initiation; Evidence={ECO:0000305};
-!- WEB RESOURCE: Name=Mutations of the TYR gene; Note=Retina
International's Scientific Newsletter;
URL="http://www.retina-international.org/files/sci-news/tyrmut.htm";
-!- WEB RESOURCE: Name=Albinism database (ADB); Note=TYR mutations;
URL="http://www.ifpcs.org/albinism/oca1mut.html";
-!- WEB RESOURCE: Name=Protein Spotlight; Note=Snowy stardom - Issue
49 of August 2004;
URL="http://web.expasy.org/spotlight/back_issues/049";
-!- WEB RESOURCE: Name=Wikipedia; Note=Tyrosinase entry;
URL="https://en.wikipedia.org/wiki/Tyrosinase";
-!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
and Haematology;
URL="http://atlasgeneticsoncology.org/Genes/TYRID42738ch11q14.html";
-----------------------------------------------------------------------
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
Distributed under the Creative Commons Attribution-NoDerivs License
-----------------------------------------------------------------------
EMBL; M27160; AAB37227.1; -; mRNA.
EMBL; M63239; AAA61242.1; -; Genomic_DNA.
EMBL; M63235; AAA61242.1; JOINED; Genomic_DNA.
EMBL; M63236; AAA61242.1; JOINED; Genomic_DNA.
EMBL; M63237; AAA61242.1; JOINED; Genomic_DNA.
EMBL; M63238; AAA61242.1; JOINED; Genomic_DNA.
EMBL; J03581; AAA61241.1; ALT_INIT; mRNA.
EMBL; Y00819; CAA68756.1; ALT_INIT; mRNA.
EMBL; U01873; AAB60319.1; ALT_SEQ; mRNA.
EMBL; M74314; AAA61244.1; -; mRNA.
EMBL; X16073; CAA34205.1; -; Genomic_DNA.
EMBL; AF237811; AAK00805.1; -; Genomic_DNA.
EMBL; AF237807; AAK00805.1; JOINED; Genomic_DNA.
EMBL; AF237808; AAK00805.1; JOINED; Genomic_DNA.
EMBL; AF237809; AAK00805.1; JOINED; Genomic_DNA.
EMBL; AF237810; AAK00805.1; JOINED; Genomic_DNA.
EMBL; BC027179; AAH27179.1; -; mRNA.
EMBL; AY012019; AAG38762.1; -; Genomic_DNA.
CCDS; CCDS8284.1; -. [P14679-1]
PIR; A38444; YRHU1.
RefSeq; NP_000363.1; NM_000372.4. [P14679-1]
UniGene; Hs.503555; -.
ProteinModelPortal; P14679; -.
BioGrid; 113150; 1.
STRING; 9606.ENSP00000263321; -.
BindingDB; P14679; -.
ChEMBL; CHEMBL1973; -.
DrugBank; DB00548; Azelaic Acid.
DrugBank; DB09526; Hydroquinone.
DrugBank; DB01055; Mimosine.
DrugBank; DB00600; Monobenzone.
DrugBank; DB00157; NADH.
iPTMnet; P14679; -.
PhosphoSitePlus; P14679; -.
BioMuta; TYR; -.
DMDM; 401235; -.
PaxDb; P14679; -.
PeptideAtlas; P14679; -.
PRIDE; P14679; -.
Ensembl; ENST00000263321; ENSP00000263321; ENSG00000077498. [P14679-1]
GeneID; 7299; -.
KEGG; hsa:7299; -.
UCSC; uc001pcs.4; human. [P14679-1]
CTD; 7299; -.
DisGeNET; 7299; -.
EuPathDB; HostDB:ENSG00000077498.8; -.
GeneCards; TYR; -.
GeneReviews; TYR; -.
HGNC; HGNC:12442; TYR.
HPA; CAB000079; -.
HPA; HPA043241; -.
HPA; HPA050889; -.
MalaCards; TYR; -.
MIM; 103470; phenotype.
MIM; 203100; phenotype.
MIM; 601800; phenotype.
MIM; 606933; gene.
MIM; 606952; phenotype.
neXtProt; NX_P14679; -.
OpenTargets; ENSG00000077498; -.
Orphanet; 352734; Minimal pigment oculocutaneous albinism type 1.
Orphanet; 352740; Ocular albinism with congenital sensorineural deafness.
Orphanet; 79431; Oculocutaneous albinism type 1A.
Orphanet; 79434; Oculocutaneous albinism type 1B.
Orphanet; 352737; Temperature-sensitive oculocutaneous albinism type 1.
PharmGKB; PA37095; -.
eggNOG; ENOG410IEZU; Eukaryota.
eggNOG; ENOG410Y42I; LUCA.
GeneTree; ENSGT00500000044790; -.
HOVERGEN; HBG003553; -.
InParanoid; P14679; -.
KO; K00505; -.
OMA; SFFSSWQ; -.
OrthoDB; EOG091G03YR; -.
PhylomeDB; P14679; -.
TreeFam; TF315865; -.
BioCyc; MetaCyc:HS01248-MONOMER; -.
BRENDA; 1.14.18.1; 2681.
Reactome; R-HSA-5662702; Melanin biosynthesis.
SABIO-RK; P14679; -.
SIGNOR; P14679; -.
GeneWiki; Tyrosinase; -.
GenomeRNAi; 7299; -.
PRO; PR:P14679; -.
Proteomes; UP000005640; Chromosome 11.
Bgee; ENSG00000077498; -.
CleanEx; HS_TYR; -.
ExpressionAtlas; P14679; baseline and differential.
Genevisible; P14679; HS.
GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
GO; GO:0005829; C:cytosol; IEA:Ensembl.
GO; GO:0005798; C:Golgi-associated vesicle; TAS:ProtInc.
GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
GO; GO:0005764; C:lysosome; TAS:UniProtKB.
GO; GO:0042470; C:melanosome; ISS:UniProtKB.
GO; GO:0033162; C:melanosome membrane; TAS:Reactome.
GO; GO:0005634; C:nucleus; IEA:Ensembl.
GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
GO; GO:0005507; F:copper ion binding; IMP:UniProtKB.
GO; GO:0004497; F:monooxygenase activity; TAS:Reactome.
GO; GO:0004503; F:monophenol monooxygenase activity; IDA:UniProtKB.
GO; GO:0046982; F:protein heterodimerization activity; ISS:UniProtKB.
GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
GO; GO:0008283; P:cell proliferation; IEA:Ensembl.
GO; GO:0006726; P:eye pigment biosynthetic process; TAS:ProtInc.
GO; GO:0042438; P:melanin biosynthetic process; IDA:CACAO.
GO; GO:0006583; P:melanin biosynthetic process from tyrosine; TAS:ProtInc.
GO; GO:0051591; P:response to cAMP; IEA:Ensembl.
GO; GO:0009411; P:response to UV; IEA:Ensembl.
GO; GO:0033280; P:response to vitamin D; IEA:Ensembl.
GO; GO:0048538; P:thymus development; IEA:Ensembl.
GO; GO:0007601; P:visual perception; TAS:ProtInc.
Gene3D; 1.10.1280.10; -; 1.
InterPro; IPR002227; Tyrosinase_Cu-bd.
InterPro; IPR008922; Unchr_di-copper_centre.
Pfam; PF00264; Tyrosinase; 1.
PRINTS; PR00092; TYROSINASE.
SUPFAM; SSF48056; SSF48056; 1.
PROSITE; PS00497; TYROSINASE_1; 1.
PROSITE; PS00498; TYROSINASE_2; 1.
1: Evidence at protein level;
Albinism; Alternative splicing; Complete proteome; Copper; Deafness;
Disease mutation; Glycoprotein; Melanin biosynthesis; Membrane;
Metal-binding; Monooxygenase; Oxidoreductase; Polymorphism;
Reference proteome; Signal; Transmembrane; Transmembrane helix;
Tumor antigen; Waardenburg syndrome.
SIGNAL 1 18 {ECO:0000255}.
CHAIN 19 529 Tyrosinase.
/FTId=PRO_0000035879.
TOPO_DOM 19 476 Lumenal, melanosome. {ECO:0000255}.
TRANSMEM 477 497 Helical. {ECO:0000255}.
TOPO_DOM 498 529 Cytoplasmic. {ECO:0000255}.
METAL 180 180 Copper A. {ECO:0000250|UniProtKB:Q9ZP19}.
METAL 202 202 Copper A. {ECO:0000250|UniProtKB:Q9ZP19}.
METAL 211 211 Copper A. {ECO:0000250|UniProtKB:Q9ZP19}.
METAL 363 363 Copper B. {ECO:0000250|UniProtKB:Q9ZP19}.
METAL 367 367 Copper B. {ECO:0000250|UniProtKB:Q9ZP19}.
METAL 390 390 Copper B. {ECO:0000250|UniProtKB:Q9ZP19}.
CARBOHYD 86 86 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
CARBOHYD 111 111 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
CARBOHYD 161 161 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
CARBOHYD 230 230 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
CARBOHYD 337 337 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
CARBOHYD 371 371 N-linked (GlcNAc...) asparagine.
{ECO:0000255}.
VAR_SEQ 346 377 GFASPLTGIADASQSSMHNALHIYMNGTMSQV -> EMGFL
HVGWAGLKLLTSRDPPPWPPKMLGLQA (in isoform
2). {ECO:0000303|PubMed:15489334}.
/FTId=VSP_006701.
VAR_SEQ 378 529 Missing (in isoform 2).
{ECO:0000303|PubMed:15489334}.
/FTId=VSP_006702.
VARIANT 19 19 H -> Q (in OCA1A; dbSNP:rs61753177).
/FTId=VAR_007649.
VARIANT 21 21 P -> S (in OCA1A; dbSNP:rs61753178).
{ECO:0000269|PubMed:1642278}.
/FTId=VAR_007650.
VARIANT 36 36 C -> Y (in OCA1A; dbSNP:rs61753179).
{ECO:0000269|PubMed:10987646}.
/FTId=VAR_021683.
VARIANT 42 42 D -> G (in OCA1A; dbSNP:rs28940878).
{ECO:0000269|PubMed:1943686}.
/FTId=VAR_007651.
VARIANT 44 44 S -> G (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021684.
VARIANT 44 44 S -> R (in OCA1A; dbSNP:rs755700581).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021685.
VARIANT 47 47 G -> D (in OCA1A; dbSNP:rs61753180).
{ECO:0000269|PubMed:11295837,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:8128955}.
/FTId=VAR_007652.
VARIANT 47 47 G -> V (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021686.
VARIANT 50 50 S -> L (in OCA1A).
{ECO:0000269|PubMed:23504663}.
/FTId=VAR_072592.
VARIANT 52 52 R -> I (in OCA1; dbSNP:rs61753182).
/FTId=VAR_007653.
VARIANT 55 55 C -> Y (in OCA1A; dbSNP:rs28940879).
{ECO:0000269|PubMed:10571953,
ECO:0000269|PubMed:1943686}.
/FTId=VAR_007654.
VARIANT 68 68 Q -> H (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021687.
VARIANT 77 77 R -> Q (in OCA1A; dbSNP:rs61753185).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:11295837,
ECO:0000269|PubMed:15146472}.
/FTId=VAR_007655.
VARIANT 77 77 R -> RR (in OCA1A).
{ECO:0000269|PubMed:10571953}.
/FTId=VAR_009236.
VARIANT 77 77 R -> W (in OCA1A; dbSNP:rs61753184).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:23504663}.
/FTId=VAR_007656.
VARIANT 79 79 S -> L (in OCA1A; dbSNP:rs544053015).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021688.
VARIANT 80 80 W -> R (in OCA1A; dbSNP:rs61753188).
/FTId=VAR_007657.
VARIANT 81 81 P -> L (in OCA1A; dbSNP:rs28940876).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:1970634}.
/FTId=VAR_007658.
VARIANT 89 89 C -> R (in OCA1A; dbSNP:rs28940877).
{ECO:0000269|PubMed:1899321}.
/FTId=VAR_007659.
VARIANT 91 91 C -> Y (in OCA1A; dbSNP:rs137854890).
{ECO:0000269|PubMed:22981120}.
/FTId=VAR_072593.
VARIANT 97 97 G -> R (in OCA1A; dbSNP:rs61753252).
{ECO:0000269|PubMed:10987646}.
/FTId=VAR_007660.
VARIANT 109 109 G -> R (in OCA1A; dbSNP:rs61753253).
{ECO:0000269|PubMed:11295837}.
/FTId=VAR_021689.
VARIANT 134 134 F -> C (in dbSNP:rs33955261).
/FTId=VAR_034576.
VARIANT 142 142 K -> N (in dbSNP:rs11545463).
/FTId=VAR_042665.
VARIANT 152 152 P -> S (in OCA1B; dbSNP:rs145513733).
{ECO:0000269|PubMed:8128955}.
/FTId=VAR_007925.
VARIANT 155 155 T -> S (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021690.
VARIANT 176 176 F -> I (in OCA1A; dbSNP:rs61753259).
{ECO:0000269|PubMed:1487241}.
/FTId=VAR_007661.
VARIANT 177 177 V -> F (in OCA1A; dbSNP:rs138487695).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021691.
VARIANT 179 179 M -> L (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021692.
VARIANT 180 180 H -> N (in OCA1A; dbSNP:rs779878377).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021693.
VARIANT 192 192 S -> Y (associated with SHEP3; light/dark
skin; dbSNP:rs1042602).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:11153699,
ECO:0000269|PubMed:11214319,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:17952075,
ECO:0000269|PubMed:17999355,
ECO:0000269|PubMed:2342539}.
/FTId=VAR_007662.
VARIANT 198 198 I -> T (in OCA1A; dbSNP:rs750553908).
{ECO:0000269|PubMed:24934919}.
/FTId=VAR_071756.
VARIANT 199 199 D -> N (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021694.
VARIANT 201 201 A -> S (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021695.
VARIANT 205 205 P -> T (in OCA1A; dbSNP:rs61754362).
{ECO:0000269|PubMed:11295837}.
/FTId=VAR_021696.
VARIANT 206 206 A -> T (in OCA1A; dbSNP:rs28940880).
{ECO:0000269|PubMed:1943686}.
/FTId=VAR_007663.
VARIANT 216 216 L -> M (in OCA1A; dbSNP:rs61754363).
/FTId=VAR_007664.
VARIANT 217 217 R -> G (in OCA1A; dbSNP:rs63159160).
/FTId=VAR_007665.
VARIANT 217 217 R -> Q (in OCA1A; dbSNP:rs61754365).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:1487241}.
/FTId=VAR_007667.
VARIANT 217 217 R -> S (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021697.
VARIANT 217 217 R -> W (in OCA1A; dbSNP:rs63159160).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:1642278}.
/FTId=VAR_007666.
VARIANT 217 217 Missing (in OCA1A).
/FTId=VAR_007926.
VARIANT 227 227 Missing (in OCA1A).
/FTId=VAR_021698.
VARIANT 236 236 W -> L (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021699.
VARIANT 236 236 W -> S (in OCA1A; dbSNP:rs61754367).
{ECO:0000269|PubMed:10987646}.
/FTId=VAR_021700.
VARIANT 239 239 R -> W (in OCA1A; dbSNP:rs774670098).
{ECO:0000269|PubMed:11858948}.
/FTId=VAR_021701.
VARIANT 240 240 D -> V (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021702.
VARIANT 243 243 K -> T (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021703.
VARIANT 253 253 G -> R (in OCA1A; dbSNP:rs61754369).
/FTId=VAR_007668.
VARIANT 256 256 H -> Y (in OCA1A; dbSNP:rs61754370).
{ECO:0000269|PubMed:11295837,
ECO:0000269|PubMed:15146472}.
/FTId=VAR_021704.
VARIANT 272 272 W -> C (in OCA1A; dbSNP:rs62645902).
{ECO:0000269|PubMed:10987646}.
/FTId=VAR_021705.
VARIANT 275 275 V -> F (in OCA1B and OCA1A;
dbSNP:rs104894314).
{ECO:0000269|PubMed:11295837,
ECO:0000269|PubMed:1903591,
ECO:0000269|PubMed:23504663}.
/FTId=VAR_007669.
VARIANT 288 288 L -> S (in OCA1A).
/FTId=VAR_007927.
VARIANT 289 289 C -> G (in OCA1A).
{ECO:0000269|PubMed:10571953}.
/FTId=VAR_009237.
VARIANT 289 289 C -> R (in OCA1A).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:15146472}.
/FTId=VAR_007670.
VARIANT 294 294 E -> G (in OCA1A).
{ECO:0000269|PubMed:10987646}.
/FTId=VAR_021706.
VARIANT 294 294 E -> K (in OCA1A and OCA1B;
dbSNP:rs757754120).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:11295837,
ECO:0000269|PubMed:8128955}.
/FTId=VAR_007928.
VARIANT 298 298 R -> W (in OCA1A; dbSNP:rs200854796).
{ECO:0000269|PubMed:23504663}.
/FTId=VAR_072594.
VARIANT 299 299 R -> H (in OCA1A; dbSNP:rs61754375).
{ECO:0000269|PubMed:10571953,
ECO:0000269|PubMed:1642278,
ECO:0000269|PubMed:8128955}.
/FTId=VAR_007671.
VARIANT 299 299 R -> S (in OCA1A; dbSNP:rs61754374).
{ECO:0000269|PubMed:10571953}.
/FTId=VAR_007672.
VARIANT 308 308 R -> T (in dbSNP:rs1042608).
/FTId=VAR_011825.
VARIANT 312 312 L -> V (in OCA1; dbSNP:rs61754377).
/FTId=VAR_007673.
VARIANT 313 313 P -> R (in OCA1; dbSNP:rs61754378).
/FTId=VAR_007674.
VARIANT 318 318 V -> E (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021707.
VARIANT 325 325 T -> A (in OCA1B; dbSNP:rs61754379).
/FTId=VAR_007675.
VARIANT 328 328 E -> Q (in OCA1A; dbSNP:rs61754380).
{ECO:0000269|PubMed:7902671}.
/FTId=VAR_007929.
VARIANT 329 329 S -> P (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021708.
VARIANT 332 332 M -> T (in OCA1A; dbSNP:rs372534292).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021709.
VARIANT 339 339 S -> G (in OCA1A; dbSNP:rs62645906).
{ECO:0000269|PubMed:11295837}.
/FTId=VAR_007676.
VARIANT 340 340 F -> L (in OCA1; dbSNP:rs62645907).
/FTId=VAR_007677.
VARIANT 345 345 E -> G (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021710.
VARIANT 346 346 G -> E (in OCA1A; dbSNP:rs773970123).
/FTId=VAR_007930.
VARIANT 355 355 A -> E (in OCA1A).
/FTId=VAR_007931.
VARIANT 355 355 A -> P (in OCA1A; dbSNP:rs62645908).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:11295837,
ECO:0000269|PubMed:15146472}.
/FTId=VAR_007678.
VARIANT 355 355 A -> V (in OCA1A; dbSNP:rs151206295).
{ECO:0000269|PubMed:23504663}.
/FTId=VAR_072595.
VARIANT 361 361 S -> R (in OCA1A; dbSNP:rs61754383).
{ECO:0000269|PubMed:8644824}.
/FTId=VAR_007932.
VARIANT 364 364 N -> H (in OCA1A).
{ECO:0000269|PubMed:23504663}.
/FTId=VAR_072596.
VARIANT 367 367 H -> Y (in OCA1A; dbSNP:rs776054795).
{ECO:0000269|PubMed:7955413}.
/FTId=VAR_007933.
VARIANT 370 370 M -> T (in OCA1A; dbSNP:rs61754385).
{ECO:0000269|PubMed:7955413}.
/FTId=VAR_007934.
VARIANT 371 371 N -> T (in OCA1A; dbSNP:rs61754387).
/FTId=VAR_007679.
VARIANT 371 371 N -> Y (in OCA1A; dbSNP:rs61754386).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:8644824}.
/FTId=VAR_007935.
VARIANT 373 373 T -> K (in OCA1A; dbSNP:rs61754388).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:11295837,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:2342539,
ECO:0000269|PubMed:23504663,
ECO:0000269|PubMed:7955413,
ECO:0000269|PubMed:8128955}.
/FTId=VAR_007680.
VARIANT 378 378 Q -> K (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021711.
VARIANT 380 380 S -> P (in OCA1B; dbSNP:rs61754391).
/FTId=VAR_007681.
VARIANT 382 382 N -> K (in OCA1A; dbSNP:rs104894315).
/FTId=VAR_007682.
VARIANT 383 383 D -> N (in OCA1A; dbSNP:rs121908011).
{ECO:0000269|PubMed:11295837,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:2342539}.
/FTId=VAR_007683.
VARIANT 384 384 P -> A (in OCA1A).
{ECO:0000269|PubMed:23504663}.
/FTId=VAR_072597.
VARIANT 390 390 H -> D (in OCA1B; dbSNP:rs62645914).
/FTId=VAR_007684.
VARIANT 393 393 V -> F (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_007936.
VARIANT 395 395 S -> N (in OCA1A; dbSNP:rs752344007).
/FTId=VAR_007685.
VARIANT 395 395 S -> R (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021712.
VARIANT 398 398 E -> A (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021713.
VARIANT 398 398 E -> V (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021714.
VARIANT 400 400 W -> L (in OCA1A; dbSNP:rs62645916).
{ECO:0000269|PubMed:10571953}.
/FTId=VAR_009238.
VARIANT 402 402 R -> G (in OCA1B).
/FTId=VAR_007937.
VARIANT 402 402 R -> L (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021715.
VARIANT 402 402 R -> Q (in dbSNP:rs1126809).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:2342539,
ECO:0000269|PubMed:7955413,
ECO:0000269|PubMed:9158138}.
/FTId=VAR_007686.
VARIANT 403 403 R -> S (in OCA1A and OCA1B;
dbSNP:rs104894316).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:1642278}.
/FTId=VAR_007687.
VARIANT 404 404 H -> N (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021716.
VARIANT 404 404 H -> P (in OCA-I; dbSNP:rs62645920).
/FTId=VAR_007688.
VARIANT 405 405 R -> L (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021717.
VARIANT 406 406 P -> L (in OCA1A and OCA1B;
dbSNP:rs104894313).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:1903591}.
/FTId=VAR_007689.
VARIANT 408 408 Q -> H (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021718.
VARIANT 409 409 E -> D (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021719.
VARIANT 416 416 A -> S (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021720.
VARIANT 417 417 P -> H (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021721.
VARIANT 419 419 G -> R (in OCA1A; dbSNP:rs61754392).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:1943686,
ECO:0000269|PubMed:7902671}.
/FTId=VAR_007690.
VARIANT 422 422 R -> Q (in OCA1A and OCA1B; temperature
sensitive variant; dbSNP:rs61754393).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:1900309}.
/FTId=VAR_007691.
VARIANT 424 424 S -> F (in OCA1A; dbSNP:rs758747581).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021722.
VARIANT 426 426 M -> K (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021723.
VARIANT 427 427 V -> G (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021724.
VARIANT 431 431 P -> L (in OCA1A; dbSNP:rs281865325).
{ECO:0000269|PubMed:7902671}.
/FTId=VAR_007938.
VARIANT 434 434 R -> I (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021725.
VARIANT 435 435 N -> D (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021726.
VARIANT 439 439 F -> V (in OCA1A; dbSNP:rs281865327).
{ECO:0000269|PubMed:10987646}.
/FTId=VAR_021727.
VARIANT 444 444 D -> G (in OCA1A).
{ECO:0000269|PubMed:15146472}.
/FTId=VAR_021728.
VARIANT 446 446 G -> S (in OCA1A; dbSNP:rs104894317).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:11295837,
ECO:0000269|PubMed:1642278}.
/FTId=VAR_007692.
VARIANT 448 448 D -> N (in OCA1A; dbSNP:rs104894318).
{ECO:0000269|PubMed:10987646,
ECO:0000269|PubMed:15146472,
ECO:0000269|PubMed:1642278}.
/FTId=VAR_007693.
VARIANT 490 490 A -> D (in OCA1A).
{ECO:0000269|PubMed:23504663}.
/FTId=VAR_072598.
CONFLICT 42 45 DRSP -> TGV (in Ref. 2; AAA61241).
{ECO:0000305}.
CONFLICT 179 179 M -> I (in Ref. 4; CAA68756).
{ECO:0000305}.
CONFLICT 373 378 TMSQVQ -> HVPGT (in Ref. 2; AAA61241).
{ECO:0000305}.
CONFLICT 495 495 L -> P (in Ref. 2; AAA61241/AAA61244).
{ECO:0000305}.
CONFLICT 520 523 DYHS -> GLPQ (in Ref. 2). {ECO:0000305}.
CONFLICT 525 528 YQSH -> VSEPFIKGLGNRVGPKSPDLTLTQSNVQVPENI
CWYFL (in Ref. 2). {ECO:0000305}.
SEQUENCE 529 AA; 60393 MW; 67211A91608A59E1 CRC64;
MLLAVLYCLL WSFQTSAGHF PRACVSSKNL MEKECCPPWS GDRSPCGQLS GRGSCQNILL
SNAPLGPQFP FTGVDDRESW PSVFYNRTCQ CSGNFMGFNC GNCKFGFWGP NCTERRLLVR
RNIFDLSAPE KDKFFAYLTL AKHTISSDYV IPIGTYGQMK NGSTPMFNDI NIYDLFVWMH
YYVSMDALLG GSEIWRDIDF AHEAPAFLPW HRLFLLRWEQ EIQKLTGDEN FTIPYWDWRD
AEKCDICTDE YMGGQHPTNP NLLSPASFFS SWQIVCSRLE EYNSHQSLCN GTPEGPLRRN
PGNHDKSRTP RLPSSADVEF CLSLTQYESG SMDKAANFSF RNTLEGFASP LTGIADASQS
SMHNALHIYM NGTMSQVQGS ANDPIFLLHH AFVDSIFEQW LRRHRPLQEV YPEANAPIGH
NRESYMVPFI PLYRNGDFFI SSKDLGYDYS YLQDSDPDSF QDYIKSYLEQ ASRIWSWLLG
AAMVGAVLTA LLAGLVSLLC RHKRKQLPEE KQPLLMEKED YHSLYQSHL


Related products :

Catalog number Product name Quantity
EIAAB44678 Homo sapiens,Human,LB24-AB,Monophenol monooxygenase,SK29-AB,Tumor rejection antigen AB,TYR,Tyrosinase
18-272-196284 Tyrosinase - Rabbit polyclonal to Tyrosinase; EC 1.14.18.1; Monophenol monooxygenase; Tumor rejection antigen AB; SK29-AB; LB24-AB Polyclonal 0.5 ml
20-272-192074 Tyrosinase - Mouse monoclonal [T311 ] to Tyrosinase; EC 1.14.18.1; Monophenol monooxygenase; Tumor rejection antigen AB; SK29-AB; LB24-AB Monoclonal 0.5 ml
18-272-196285 Tyrosinase prediluted - Rabbit polyclonal to Tyrosinase prediluted; EC 1.14.18.1; Monophenol monooxygenase; Tumor rejection antigen AB; SK29-AB; LB24-AB Polyclonal 7 ml
M-0913 (Val438)-Tyrosinase (432-444) (human) (Val438)-LB24-AB (432-444) (human), (Val438)-Monophenol Monooxygenase (432-444) (human), (Val438)-SK29-AB (432-444) (human), (Val438)-Tumor Rejection Antigen AB ( 5mg
EIAAB44675 Bos taurus,Bovine,Monophenol monooxygenase,TYR,Tyrosinase
EIAAB44679 Albino locus protein,Monophenol monooxygenase,Mouse,Mus musculus,Tyr,Tyrosinase
20-783-74695 MOUSE ANTI HUMAN TYROSINASE - EC 1.14.18.1; Monophenol monooxygenase; Albino locus protein Monoclonal 0.1 ml
EIAAB44677 Chicken,Gallus gallus,Monophenol monooxygenase,TYR,Tyrosinase
29-012 SART3 is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in ca 0.1 mg
EIAAB44676 Canis familiaris,Canis lupus familiaris,Dog,Monophenol monooxygenase,TYR,Tyrosinase
gen12074 ENPL_HUMAN Tumor rejection antigen 1 ELISA tesk kit 1
gen12086 ENPL_MOUSE Tumor rejection antigen gp96 ELISA tesk kit 1
EIAAB44547 Mouse,Mus musculus,P1a,Trap1a,Tumor rejection antigen P815A
gen12083 ENPL_MOUSE Polymorphic tumor rejection antigen 1 ELISA tesk kit 1
201-20-6632 HSP90B1{Homo sapiens tumor rejection antigen (gp96) 1}mouse.mAb 0.2ml
201-20-2648 HSP90B1{Homo sapiens tumor rejection antigen (gp96) 1}rabbit.pAb 0.2ml
MEDCLA769 MAGE_1, Tumor Rejection Antigen, Clone 6C1, Mab anti_Human; paraffin_NO frozen, IH_No WB 1 ml.
EIAAB08679 70 kDa WD repeat tumor rejection antigen,Coro7,Coronin-7,Crn7,Rat,Rattus norvegicus
EIAAB08682 70 kDa WD repeat tumor rejection antigen homolog,Coro7,Coronin-7,Crn7,Mouse,Mus musculus
EIAAB37305 Kiaa0156,Mouse,mSART-3,Mus musculus,Sart3,SART-3,Squamous cell carcinoma antigen recognized by T-cells 3,Tumor-rejection antigen SART3
GWB-142A67 Tumor Rejection Antigen (GP96) 1 (HSP90B1) Rabbit anti-Human Polyclonal (C-Terminus) Antibody
GWB-40351B Tumor Rejection Antigen (GP96) 1 (HSP90B1) Rabbit anti-Human Polyclonal (aa590-640) Antibody
EIAAB08681 70 kDa WD repeat tumor rejection antigen homolog,CORO7,Coronin-7,Crn7,Homo sapiens,Human
18-003-44186 Endoplasmin - Heat shock protein 90 kDa beta member 1; 94 kDa glucose-regulated protein; GRP94; gp96 homolog; Tumor rejection antigen 1 Polyclonal 0.1 mg Protein A


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur